|
Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer Clinical research trials and Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer. Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer clinical trial. Human subjects frequently get the finest healthcare available for their Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer  Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer
Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer
For Condition: recurrent renal cell cancer,stage 4 renal cell cancer
Status: Recruiting
Sponsor(s): Federation Nationale des Centres de Lutte Contre le Cancer ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic stem cell transplantation in treating patients who have metastaticrenal cell cancer (kidney cancer).
Details: OBJECTIVES: - Determine the 18-month survival rate of patients with metastatic renal cell carcinoma treated with allogeneic stem cell transplantation. - Determine the objective rate of response of patients treated with this regimen. - Determine post-transplant immunological reactions and recuperation of patients treated with this regimen. - Determine the antitumoral activity of this regimen in these patients. OUTLINE: This is a non-randomized, multicenter study. Patients are assigned to 1 of 2 treatment groups based on availability of a compatible family member for stem cell transplantation. - Group I: Patients with a compatible family donor receive conditioning chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 and fludarabine IV once daily on days -5 to -1. Patients undergo filgrastim (G-CSF)-mobilized allogeneic stem cell transplantation on day 0. Patients also receive immunosuppression therapy with cyclosporine beginning on day -2. Patients who have persistent or progressive disease, mixed chimerism, and no evidence of grade 2 or greater graft-vs-host disease, and have been off immunosuppression therapy for 1-2 weeks receive donor lymphocyte infusion on days 7 and 21. - Group II: Patients without a compatible family donor receive treatment (immunotherapy, vaccination therapy, or chemotherapy) at the discretion of the treating physician. Patients are followed every 3 months for 5 years. PROJECTED ACCRUAL: A total of 170 patients (60 patients for group I and 110 patients for group II) will be accrued for this study within 3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic renal cell carcinoma - No sarcomatoid, pure papillary, or Bellini renal cell cancer - Measurable and/or evaluable disease - Disease progression after at least 1 immunotherapy regimen for metastatic disease - Localized metastases allowed provided the following are true: - At least 3 months since prior treatment for metastases - Not considered likely to influence outcome of transplantation - No brain metastases unless treated surgically or radiologically and MRI normal - Sufficiently healthy, HLA-compatible family member must be available as donor for patients undergoing stem cell transplantation PATIENT CHARACTERISTICS: Age - 18 to 65 Performance status - ECOG 0-1 Life expectancy - More than 6 months Hematopoietic - Platelet count at least 100,000/mm^3 Hepatic - Transaminases less than 1.5 times upper limit of normal (ULN)* - Bilirubin less than 1.5 times ULN* NOTE: *Unless due to Gilbert's disease Renal - No renal insufficiency - Calcium less than 10.4 mg/dL - Creatinine clearance greater than 50 mL/min Cardiovascular - Ejection fraction greater than 50% Pulmonary - No DLCO that would preclude fludarabine or busulfan therapy Other - Not pregnant or nursing - Fertile patients must use effective contraception - No physical obstacle to receiving study treatment - No known autoimmune disease - No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix - No uncontrolled bacterial, viral, or fungal infection - No prior or concurrent psychiatric disease - HIV negative - HTLV1 negative PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - No tolerance to fludarabine and busulfan Endocrine therapy - No concurrent corticosteroids Radiotherapy - Not specified Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DidierBlaise, Study Chair, Institut J. Paoli and I. Calmettes
Institut J. Paoli and I. Calmettes *Recruiting*
Marseille, , 13273
France
Recruiting Didier Blaise 33-4-91-22-37-54
Additional Information:
Study ID Numbers: CDR0000271936; EU-20234,FRE-FNCLCC-GETUG-11/0105
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056095
Other Recurrent Renal Cell Cancer Studies:
1. Chemotherapy in Treating Patients With Advanced Kidney Cancer
2. Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
3. High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
4. Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
5. BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
Related Studies:
Other recurrent renal cell cancer Clinical Trials
Other Clinical Trials
Other Marseille Clinical Trials
Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer
|
|
|
|
|
|
|
|
